Патогенетическое обоснование применения фенспирида (эреспала) при бронхиальной астме у детей

We observed 31 children received fenspirid (Erespal) including 15 bronchial asthma children (the study group) and 16 children with chronic non-specific inflammatory bronchopulmonary diseases (the comparative group). The bronchial asthmatic children showed increased H 1 -receptors sensitivity for histamine accompanied by exceeded intracellular calcium ion concentration as a response to the histamine stimulation. They also showed an increase of ɑ 1 -adrenoreceptors number. Meantime the intracellular calcium ion concentration arise less than it was in the children with chronic non-specific inflammatory bronchopulmonary diseases under the noradrenaline stimulation. Against the background of treatment with fenspirid (Erespal) the H 1 -histamine receptors sensitivity as well as calcium ions response to histamine and noradrenalin stimulations decreased in the bronchial asthma children and the similar events appeared in less degree after the histamine stimulation in children with chronic inflammatory bronchopulmonary diseases. Simultaneously clinical bronchial obstruction signs solved and lung function improved.